NHS大格拉斯哥和克莱德公司研究Favipiravir作为苏格兰轻度至中度COVID-19的早期发作治疗
苏格兰
已启动一项基于favipiravir的研究，调查针对该喀里多尼亚针对COVID-19病例的抗病毒药物的疗效和安全性。
由格拉斯哥大学在格拉斯哥临床研究机构的支持下组织，
多亏了苏格兰政府首席科学家办公室的资助，
CRUK临床试验部门主任首席研究员Rob Jones
领导一个团队，目前正在这里招募参与者，以帮助为对抗冠状病毒的战争做出贡献。
基于非维拉韦的研究
能在俄罗斯和其他几个国家/地区获得批准用于COVID-19临床治疗的favipiravir，
帮助苏格兰初发，轻度至中度COVID-19病例的患者？
The Study
The NHS Greater Glasgow and Clyde and the University of Glasgow guide the study known here as the Glasgow Early Treatment Arm Favipiravir (GETAFIX) study.
Studying the impact of favipiravir, whether the antiviral can reduce the time it takes to recover, prominent local hospitals serve as trial sites.
These sites include three NHSGGC hospitals, including
Queen Elizabeth University Hospital, Glasgow Royal Infirmary and Royal Alexandra Hospital and a designated outpatient facility for treating patients out in the community.
Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial | Trials | Full Text
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04891-1